ATE413173T1 - Phenylpiperazin-derivate mit einer kombination aus teilweisem dopamin-d2-rezeptor-agonismus und serotonin-wiederaufnahmehemmung - Google Patents

Phenylpiperazin-derivate mit einer kombination aus teilweisem dopamin-d2-rezeptor-agonismus und serotonin-wiederaufnahmehemmung

Info

Publication number
ATE413173T1
ATE413173T1 AT05816322T AT05816322T ATE413173T1 AT E413173 T1 ATE413173 T1 AT E413173T1 AT 05816322 T AT05816322 T AT 05816322T AT 05816322 T AT05816322 T AT 05816322T AT E413173 T1 ATE413173 T1 AT E413173T1
Authority
AT
Austria
Prior art keywords
inhibition
serotonin
reuppost
combination
phenylpiperazine derivatives
Prior art date
Application number
AT05816322T
Other languages
English (en)
Inventor
Roelof W Feenstra
Axel Stoit
Jan-Willem Terpstra
Maria L Pras-Raves
Andrew C Mccreary
Vliet Bernard Van
Mayke Hesselink
Cornelis Kruse
Scharrenburg G J M Van
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Application granted granted Critical
Publication of ATE413173T1 publication Critical patent/ATE413173T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)
AT05816322T 2004-12-08 2005-12-06 Phenylpiperazin-derivate mit einer kombination aus teilweisem dopamin-d2-rezeptor-agonismus und serotonin-wiederaufnahmehemmung ATE413173T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63407404P 2004-12-08 2004-12-08
EP04106394 2004-12-08

Publications (1)

Publication Number Publication Date
ATE413173T1 true ATE413173T1 (de) 2008-11-15

Family

ID=35744728

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05850037T ATE401883T1 (de) 2004-12-08 2005-12-06 Aryloxyethylaminderivate mit einer kombination aus partiellem dopamin-d2-rezeptoragonismus und serotonin-wiederaufnahmehemmung
AT05816322T ATE413173T1 (de) 2004-12-08 2005-12-06 Phenylpiperazin-derivate mit einer kombination aus teilweisem dopamin-d2-rezeptor-agonismus und serotonin-wiederaufnahmehemmung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05850037T ATE401883T1 (de) 2004-12-08 2005-12-06 Aryloxyethylaminderivate mit einer kombination aus partiellem dopamin-d2-rezeptoragonismus und serotonin-wiederaufnahmehemmung

Country Status (18)

Country Link
EP (4) EP1827426A1 (de)
JP (4) JP2008523030A (de)
KR (4) KR20070085988A (de)
AT (2) ATE401883T1 (de)
AU (4) AU2005313312A1 (de)
BR (1) BRPI0518613A2 (de)
CA (4) CA2587559A1 (de)
DE (2) DE602005010902D1 (de)
DK (2) DK1827427T3 (de)
ES (2) ES2317335T3 (de)
HR (2) HRP20080538T3 (de)
IL (4) IL183062A0 (de)
NO (4) NO20072974L (de)
PL (2) PL1827427T3 (de)
PT (2) PT1824479E (de)
RU (4) RU2007125659A (de)
SI (2) SI1827427T1 (de)
WO (4) WO2006061377A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007085651A1 (en) * 2006-01-30 2007-08-02 Speedel Experimenta Ag Process for the stereoselective preparation of alcohols from alpha, beta- insaturated compounds
US8063062B2 (en) 2006-12-20 2011-11-22 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition
CA2671554A1 (en) * 2007-01-10 2008-07-17 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition
US8138174B2 (en) 2007-01-10 2012-03-20 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition
EP2148879B1 (de) * 2007-04-23 2012-11-28 Janssen Pharmaceutica, N.V. Thia(dia)zole als schnell dissoziierende dopamin-2-rezeptorantagonisten
US20100137368A1 (en) * 2007-04-23 2010-06-03 Janssen Pharmaceutica N.V. Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
US8906921B2 (en) * 2007-04-23 2014-12-09 Janssen Pharmaceutica Nv 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
CN103360342B (zh) * 2012-04-09 2015-12-16 江苏恩华药业股份有限公司 3-氰基苯胺烷基芳基哌嗪衍生物及在制备药物中的应用
CN103570698B (zh) * 2012-08-01 2016-08-03 江苏恩华药业股份有限公司 用于制备维拉佐酮的化合物及其中间体和应用
ITMI20130392A1 (it) * 2013-03-15 2014-09-16 Dipharma Francis Srl Sintesi di un inibitore della ricaptazione della serotonina
AU2014282769A1 (en) 2013-06-21 2015-12-17 Lupin Limited Substituted heterocyclic compounds as CRAC modulators
WO2014207648A1 (en) 2013-06-24 2014-12-31 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
US9598401B2 (en) 2013-07-29 2017-03-21 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692264B1 (fr) * 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
EP0900792B1 (de) * 1997-09-02 2003-10-29 Duphar International Research B.V Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
CN1304403A (zh) * 1998-04-08 2001-07-18 美国家用产品公司 用于治疗抑郁症的n－芳氧基乙基－吲哚基－烷基胺(5－ht1a受体活化剂)
NZ508506A (en) * 1998-06-19 2004-01-30 H 4,5,6 and 7-indole and indoline derivatives, their preparation and use
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
SK287018B6 (sk) * 1999-08-23 2009-09-07 Solvay Pharmaceuticals B. V. Deriváty fenylpiperazínov, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitie
PL375350A1 (en) * 2002-12-10 2005-11-28 Merck Patent Gmbh Indol derivatives and their use as 5-ht ligands

Also Published As

Publication number Publication date
KR20070085916A (ko) 2007-08-27
JP2008523029A (ja) 2008-07-03
RU2007125661A (ru) 2009-01-20
DE602005008471D1 (de) 2008-09-04
NO20072981L (no) 2007-09-05
EP1827427B1 (de) 2008-07-23
EP1824479B1 (de) 2008-11-05
JP2008537725A (ja) 2008-09-25
SI1827427T1 (sl) 2008-12-31
AU2005313390A1 (en) 2006-06-15
AU2005313312A1 (en) 2006-06-15
WO2006061378A1 (en) 2006-06-15
CA2587559A1 (en) 2006-06-15
RU2007125658A (ru) 2009-01-20
IL183061A0 (en) 2007-09-20
NO20072974L (no) 2007-08-23
PT1824479E (pt) 2009-01-30
HRP20090015T3 (en) 2009-02-28
DE602005010902D1 (de) 2008-12-18
EP1824479A1 (de) 2007-08-29
CA2587381A1 (en) 2006-06-15
ES2311245T3 (es) 2009-02-01
WO2006061376A1 (en) 2006-06-15
DK1824479T3 (da) 2009-03-09
KR20070085975A (ko) 2007-08-27
SI1824479T1 (sl) 2009-04-30
HRP20080538T3 (en) 2008-12-31
RU2007125660A (ru) 2009-01-20
PT1827427E (pt) 2008-11-03
ES2317335T3 (es) 2009-04-16
WO2006061379A1 (en) 2006-06-15
NO20072969L (no) 2007-08-31
IL183062A0 (en) 2007-09-20
CA2587202A1 (en) 2006-06-15
EP1824480A1 (de) 2007-08-29
JP2008523030A (ja) 2008-07-03
KR20070085959A (ko) 2007-08-27
PL1824479T3 (pl) 2009-04-30
CA2587357A1 (en) 2006-06-15
AU2005313391A1 (en) 2006-06-15
WO2006061377A1 (en) 2006-06-15
RU2007125659A (ru) 2009-01-20
NO20072977L (no) 2007-09-05
EP1827426A1 (de) 2007-09-05
AU2005313311A1 (en) 2006-06-15
ATE401883T1 (de) 2008-08-15
BRPI0518613A2 (pt) 2008-11-25
PL1827427T3 (pl) 2009-01-30
JP2008523031A (ja) 2008-07-03
DK1827427T3 (da) 2008-11-24
IL183064A0 (en) 2007-09-20
KR20070085988A (ko) 2007-08-27
EP1827427A1 (de) 2007-09-05
IL183063A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
ATE401883T1 (de) Aryloxyethylaminderivate mit einer kombination aus partiellem dopamin-d2-rezeptoragonismus und serotonin-wiederaufnahmehemmung
RS51970B (en) TRICYCLIC UNITS AND THEIR USE AS MODULATORS OF GLUCOCORTICOID RECEPTORS
PE20081690A1 (es) Sal de tosilato de un compuesto terapeutico y composiciones farmaceuticas de la misma
DE602008004265D1 (de) Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
GEP20146124B (en) Novel ccr2 receptor antagonists and usage thereof
ECSP109922A (es) Compuestos de pirazol y su uso como inhibidores raf
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
CR11463A (es) Compuestos de piridilmetil-sulfonamida
MX2009003713A (es) Inhibidor de progresion de enfermedad de alzheimer que contiene un compuesto heterociclico con estructura especifica.
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
UY31133A1 (es) "oxazolidinonas sustituidas y su uso"
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
TW200631952A (en) Benzdioxan piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
TW200633987A (en) Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
ECSP109874A (es) Nuevos compuestos 892
TW200634009A (en) Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
RS53747B1 (en) FENANTRENON UNITS, COMPOSITIONS AND METHODS
UY31668A1 (es) "ligando de receptor d2-078"
EA200970710A1 (ru) ПРОИЗВОДНЫЕ 2-ПИПЕРАЗИН-1-ИЛ-3Н-ИМИДАЗО[4,5-b]ПИРИДИНА
NO20073390L (no) Fenylpiperaziner med en kombinasjon av affinitet for dopamin-D2-reseptorer og serotoningjenopptaksseter

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1824479

Country of ref document: EP

REN Ceased due to non-payment of the annual fee